Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APHATSE:AUPNASDAQ:CARANYSE:PBH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPHAAphria$15.38$15.48$2.78▼$32.29$4.87B2.6721.83 million shsN/AAUPAurinia PharmaceuticalsC$0.00C$11.77▼C$26.00C$2.15BN/A229,895 shs4.61 million shsCARACara Therapeutics$15.19$8.13▼$26.28$24.33M0.4124,502 shs237,144 shsPBHPrestige Consumer Healthcare$84.52+0.2%$83.60$62.35▼$90.04$4.18B0.44297,189 shs38,352 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPHAAphria0.00%0.00%0.00%0.00%0.00%AUPAurinia Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CARACara Therapeutics0.00%0.00%0.00%+10.14%-34.02%PBHPrestige Consumer Healthcare-1.71%-0.22%+4.12%+0.67%+33.48%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPHAAphriaN/AN/AN/AN/AN/AN/AN/AN/AAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACARACara Therapeutics1.6275 of 5 stars3.00.00.04.20.00.80.0PBHPrestige Consumer Healthcare4.119 of 5 stars2.32.01.73.53.12.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPHAAphria 0.00N/AN/AN/AAUPAurinia Pharmaceuticals 0.00N/AN/AN/ACARACara Therapeutics 2.00Hold$36.00∞ UpsidePBHPrestige Consumer Healthcare 2.50Moderate Buy$93.3310.43% UpsideCurrent Analyst Ratings BreakdownLatest CARA, APHA, PBH, and AUP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/8/2025PBHPrestige Consumer HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold3/21/2025PBHPrestige Consumer HealthcareRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$96.00 ➝ $97.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPHAAphria$405.96M12.00$0.09 per share166.43$4.80 per share3.20AUPAurinia PharmaceuticalsC$57.59M0.00N/A6.75C$2.59 per share0.00CARACara Therapeutics$7.14M0.00N/AN/A$12.58 per share0.00PBHPrestige Consumer Healthcare$1.14B3.67$4.96 per share17.03$36.10 per share2.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPHAAphria-$63.21M-$0.06N/A219.71N/A-36.10%-2.30%-1.66%N/AAUPAurinia PharmaceuticalsN/A-C$1.48N/AN/AN/AN/AN/AN/AN/ACARACara Therapeutics-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/APBHPrestige Consumer Healthcare$209.34M$4.2919.7917.762.6919.13%12.36%6.39%8/14/2025 (Estimated)Latest CARA, APHA, PBH, and AUP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPHAAphriaN/AN/AN/AN/AN/AAUPAurinia PharmaceuticalsN/AN/AN/AN/AN/ACARACara TherapeuticsN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare$1.902.25%N/A44.29%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPHAAphria0.252.361.17AUPAurinia Pharmaceuticals2.6911.9311.02CARACara TherapeuticsN/A4.774.71PBHPrestige Consumer Healthcare0.563.682.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPHAAphria10.30%AUPAurinia PharmaceuticalsN/ACARACara Therapeutics44.66%PBHPrestige Consumer Healthcare99.95%Insider OwnershipCompanyInsider OwnershipAPHAAphriaN/AAUPAurinia PharmaceuticalsN/ACARACara Therapeutics3.10%PBHPrestige Consumer Healthcare1.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPHAAphria1,200316.80 millionN/AOptionableAUPAurinia Pharmaceuticals300128.40 millionN/ANot OptionableCARACara Therapeutics804.57 million4.43 millionOptionablePBHPrestige Consumer Healthcare54049.42 million48.75 millionOptionableCARA, APHA, PBH, and AUP HeadlinesRecent News About These CompaniesPublic Employees Retirement System of Ohio Lowers Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 29 at 4:49 AM | marketbeat.comVise Technologies Inc. Acquires Shares of 4,085 Prestige Consumer Healthcare Inc. (NYSE:PBH)May 29 at 4:31 AM | marketbeat.comTwo Sigma Advisers LP Sells 18,300 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)May 29 at 4:18 AM | marketbeat.comTwo Sigma Investments LP Has $6.50 Million Stock Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 28 at 4:09 AM | marketbeat.comPrestige Consumer Gains 35.7% in a Year: What's Driving the Stock?May 27 at 9:15 AM | zacks.com1,087,620 Shares in Prestige Consumer Healthcare Inc. (NYSE:PBH) Bought by Kayne Anderson Rudnick Investment Management LLCMay 27 at 5:54 AM | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Holdings Decreased by Nuveen Asset Management LLCMay 27 at 3:53 AM | marketbeat.comNorth Star Asset Management Inc. Cuts Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 26 at 6:16 AM | marketbeat.comProShare Advisors LLC Grows Stock Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 25, 2025 | marketbeat.comFocus Partners Wealth Acquires Shares of 3,015 Prestige Consumer Healthcare Inc. (NYSE:PBH)May 25, 2025 | marketbeat.comDeutsche Bank AG Purchases 14,929 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)May 23, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Position Reduced by Ameriprise Financial Inc.May 23, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Westwood Holdings Group Inc.May 21, 2025 | marketbeat.comPrestige Consumer Healthcare (NYSE:PBH) Upgraded to "Buy" at StockNews.comMay 19, 2025 | marketbeat.comPrestige Consumer Healthcare (NYSE:PBH) Raised to Buy at StockNews.comMay 19, 2025 | americanbankingnews.comLazard Asset Management LLC Raises Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 17, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Has $10.94 Million Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)May 17, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Stake Increased by Bank of America Corp DEMay 17, 2025 | marketbeat.comPrestige Consumer Healthcare Inc. (NYSE:PBH) Shares Sold by Jane Street Group LLCMay 17, 2025 | marketbeat.comPBH vs. ESLOY: Which Stock Should Value Investors Buy Now?May 14, 2025 | zacks.comPrestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin IncreaseMay 13, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumU.S. Regulators Target CrowdStrike: Is It a Signal or Noise? By Chris Markoch | May 14, 2025View U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? APHA, PBH, AUP, and CARA Company DescriptionsAphria NASDAQ:APHAAphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.Aurinia Pharmaceuticals TSE:AUPAurinia Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Cara Therapeutics NASDAQ:CARACara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.Prestige Consumer Healthcare NYSE:PBH$84.32 -0.03 (-0.04%) As of 11:34 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? CrowdStrike Stock Slips: Analyst Downgrades Before Earnings AutoZone Stock to Cross $4400 This Year: This Is Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
